Immunotherapy of rheumatoid arthritis targeting inflammatory cytokines and autoreactive T cells

Archivum Immunologiae et Therapiae Experimentalis

Volumn 58, Issue 1, 2010, Pages 27-36

  Chen, Guangjie ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Autoreactive T cells; Immunotherapy; Inflammatory cytokines; Regulatory T cells; Rheumatoid arthritis; Th17 cells

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEMTUZUMAB; AMG 108; AMG 714; ANTIRHEUMATIC AGENT; AUTOANTIGEN; COLLAGEN TYPE 2; CYTOKINE; CYTOKINE RECEPTOR ANTAGONIST; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 5 RECEPTOR; INTERLEUKIN 6; LEFLUNOMIDE; METHOTREXATE; MONOCLONAL ANTIBODY; OKT 4; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; T CELL VACCINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; VACCINE;

ABSENCE OF SIDE EFFECTS; ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; CARDIOTOXICITY; CELL PROLIFERATION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INJECTION SITE REACTION; MEDIATOR; MONOTHERAPY; NONHUMAN; PATHOGENESIS; QUALITY OF LIFE; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SKIN MANIFESTATION; SYMPTOM; T LYMPHOCYTE; TREATMENT DURATION; VACCINATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ARTHRITIS, RHEUMATOID; COLLAGEN TYPE II; CYTOKINES; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; T-LYMPHOCYTES;

EID: 76649105764     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-009-0058-1     Document Type: Review

References (94)

1. EV Acosta-Rodriguez L Rivino J Geginat, et al. 2007 Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells Nat Immunol 8 639 846 10.1038/ni1467 17486092 (Pubitemid 46785128)
2. B Afzali G Lombardi RI Lechler, et al. 2007 The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease Clin Exp Immunol 148 32 46 17328715
3. J Ahlen S Andersson H Mukohyama, et al. 2002 Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones Bone 31 242 251 10.1016/S8756-3282(02)00784-6 12110441 (Pubitemid 34754454)
4. T Alonzi E Fattori D Lazzaro, et al. 1998 Interleukin 6 is required for the development of collagen-induced arthritis J Exp Med 187 461 468 10.1084/jem.187.4.461 9463396 (Pubitemid 28093348)
5. AK Andersson M Feldmann FM Brennan 2008 Neutralizing IL-21 and IL-15 inhibits pro-inflammatory cytokine production in rheumatoid arthritis Scand J Immunol 68 103 111 10.1111/j.1365-3083.2008.02118.x 18482208 (Pubitemid 351798402)
6. SM Anderton R van der Zee B Prakken, et al. 1995 Activation of T cells recognizing self 60-kD heat shock protein can protect against experimental arthritis J Exp Med 181 943 952 10.1084/jem.181.3.943 7869052
7. SF Ausar DM Beltramo LF Castagna, et al. 2001 Treatment of rheumatoid arthritis by oral administration of bovine tracheal type II collagen Rheumatol Int 20 138 144 10.1007/s002960100099 11411957 (Pubitemid 32449110)
8. LM Bang GM Keating 2004 Adalimumab: a review of its use in rheumatoid arthritis BioDrugs 18 121 139 10.2165/00063030-200418020-00005 15046527 (Pubitemid 38507894)
9. ML Barnett D Combitchi DE Trentham 1996 A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis Arthritis Rheum 39 623 628 10.1002/art.1780390413 8630112 (Pubitemid 26118041)
10. ML Barnett JM Kremer EM St Clair, et al. 1998 Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial Arthritis Rheum 41 290 297 10.1002/1529-0131(199802)41: 2<290::AID-ART13>3.0.CO;2-R 9485087 (Pubitemid 28087697)
11. B Baslund N Tvede B Danneskiold-Samsoe 2005 Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study Arthritis Rheum 52 2686 2692 10.1002/art.21249 16142748 (Pubitemid 41369096)
12. F Bazzoni B Beutler 1996 The tumor necrosis factor ligand and receptor families N Engl J Med 334 1717 1725 10.1056/NEJM199606273342607 8637518 (Pubitemid 26193625)
13. E Bettelli Y Carrier W Gao, et al. 2006 Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells Nature 441 235 238 10.1038/nature04753 16648838
14. HC Blair NA Athanasou 2004 Recent advances in osteoclast biology and pathological bone resorption Histol Histopathol 19 189 199 14702187
15. F Capsoni P Sarzi-Puttini F Atzeni, et al. 2005 Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis Arthritis Res Ther 7 R250 R255 10.1186/ar1477 15743471
16. AI Catrina J Lampa S Ernestam, et al. 2002 Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis Rheumatology 41 484 489 10.1093/rheumatology/41.5.484 12011369
17. AI Catrina E af Klint S Ernestam, et al. 2006 Anti-tumor necrosis factor therapy increases synovial osteo-protegerin expression in rheumatoid arthritis Arthritis Rheum 54 76 81 10.1002/art.21528 16385498 (Pubitemid 43122189)
18. M Chabaud JM Durand N Buchs, et al. 1999 Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium Arthritis Rheum 42 963 970 10.1002/1529-0131(199905)42:5<963::AID-ANR15>3. 0.CO;2-E 10323452 (Pubitemid 29215007)
19. P Charles MJ Elliott D Davis, et al. 1999 Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis J Immunol 163 1521 1528 10415055
20. G Chen N Li YC Zang, et al. 2007 Vaccination with selected synovial T cells in rheumatoid arthritis Arthritis Rheum 56 453 463 10.1002/art.22316 17265481 (Pubitemid 46271972)
21. Z Chen CM Tato L Muul, et al. 2007 Distinct regulation of interleukin in human T helper lymphocytes Arthritis Rheum 56 2936 2946 10.1002/art.22866 17763419 (Pubitemid 47502740)
22. EH Choy GS Panayi 2001 Cytokine pathways and joint inflammation in rheumatoid arthritis N Engl J Med 344 907 916 10.1056/NEJM200103223441207 11259725 (Pubitemid 32224400)
23. EH Choy DA Isenberg T Garrood, et al. 2002 Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial Arthritis Rheum 46 3143 3150 10.1002/art.10623 12483717 (Pubitemid 35453522)
24. RJ Dolhain AN van der Heiden NT ter Haar, et al. 1996 Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis Arthritis Rheum 39 1961 1969 10.1002/art.1780391204 8961900 (Pubitemid 27009063)
25. V Ducoulombier E Solau P Coquerelle, et al. 2007 Long-term results of infliximab therapy in rheumatoid arthritis: experience acquired by the North-Pas-de-Calais hospital network Joint Bone Spine 74 56 59 10.1016/j.jbspin.2006.03.008 17182267 (Pubitemid 46251508)
26. MR Ehrenstein JG Evans A Singh, et al. 2004 Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF alpha therapy J Exp Med 200 277 285 10.1084/jem.20040165 15280421 (Pubitemid 39031247)
27. P Emery 2003 The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis Expert Opin Investig Drugs 12 673 681 10.1517/13543784.12.4.673 12665422 (Pubitemid 36512011)
28. M Feldmann FM Brennan RN Maini 1996 Rheumatoid arthritis Cell 85 307 310 10.1016/S0092-8674(00)81109-5 8616886 (Pubitemid 26160702)
29. GS Firestein WD Xu K Townsend, et al. 1988 Cytokines in chronic inflammatory arthritis. I. Failure to detect T cell lymphokines (interleukin 2 and interleukin 3) and presence of macrophage colony-stimulating factor (CSF-1) and a novel mast cell growth factor in rheumatoid synovitis J Exp Med 168 1573 1586 10.1084/jem.168.5.1573 3263464 (Pubitemid 19023248)
30. J Fishman-Lobell A Friedman HL Weiner 1994 Different kinetic patterns of cytokine gene expression in vivo in orally tolerant mice Eur J Immunol 24 2720 2724 10.1002/eji.1830241122 7957564 (Pubitemid 24342188)
31. M Fujimoto S Serada M Mihara, et al. 2008 Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses Arthritis Rheum 58 3710 3719 10.1002/art.24126 19035481
32. J Furuzawa-Carballeda MI Vargas-Rojas AR Cabral 2007 Autoimmune inflammation from the Th17 perspective Autoimmun Rev 6 169 175 10.1016/j.autrev.2006.10.002 17289553 (Pubitemid 46187336)
33. JS Gaston 2008 Cytokines in arthritis-the 'big numbers' move centre stage Rheumatology 47 8 12 10.1093/rheumatology/kem203 17715172 (Pubitemid 350286255)
34. SR Goldring EM Gravallese 2002 Pathogenesis of bone lesions in rheumatoid arthritis Curr Rheumatol Rep 4 226 231 10.1007/s11926-002-0069-y 12010607
35. I Goldstein S Ben-Horin A Koltakov, et al. 2007 Alpha1beta1 Integrin+ and regulatory Foxp3+ T cells constitute two functionally distinct human CD4+ T cell subsets oppositely modulated by TNFalpha blockade J Immunol 178 201 210 17182556
36. I Gutcher B Becher 2007 APC-derived cytokines and T cell polarization in autoimmune inflammation J Clin Invest 117 1119 1127 10.1172/JCI31720 17476341 (Pubitemid 46718396)
37. G Harriman LK Harper TF Schaible 1999 Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNF alpha treatment Ann Rheum Dis 58 Suppl 1 i61 i64 10.1136/ard.58.2008.i61 10577975
38. M Hashizume N Hayakawa M Mihara 2008 IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17 Rheumatology 47 1635 1640 10.1093/rheumatology/ ken363 18786965
39. T Hlavaty M Pierik L Henckaerts, et al. 2005 Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease Aliment Pharmacol Ther 22 613 626 10.1111/j.1365-2036.2005.02635.x 16181301 (Pubitemid 41415989)
40. BW Kirkham MN Lassere JP Edmonds, et al. 2006 Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the damage study cohort) Arthritis Rheum 54 1122 1131 10.1002/art.21749 16572447 (Pubitemid 43672925)
41. T Kishimoto 2005 Interleukin-6: from basic science to medicine-40 years in immunology Annu Rev Immunol 23 1 21 10.1146/annurev.immunol.23.021704.115806 15771564 (Pubitemid 40563163)
42. L Klareskog M Gaubitz V Rodriguez-Valverde, et al. 2006 A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs Ann Rheum Dis 65 1578 1584 10.1136/ard.2005.038349 16540554 (Pubitemid 44799668)
43. A Klinkhoff 2004 Biological agents for rheumatoid arthritis: targeting both physical function and structural damage Drugs 64 1267 1283 10.2165/00003495-200464120-00001 15200343 (Pubitemid 38916341)
44. JM Kremer R Westhovens M Leon, et al. 2003 Treatment of rheumatoid arthritis by selective inhibition of T cell activation with fusion protein CTLA4Ig N Engl J Med 349 1907 1915 10.1056/NEJMoa035075 14614165 (Pubitemid 37409707)
45. JM Kremer M Dougados P Emery, et al. 2005 Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial Arthritis Rheum 52 2263 2271 10.1002/art.21201 16052582 (Pubitemid 41117408)
46. JM Kremer HK Genant LW Moreland, et al. 2006 Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial Ann Intern Med 144 865 876 16785475
47. JM Kremer HK Genant LW Moreland, et al. 2008 Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate Arthritis Rheum 58 953 963 10.1002/art.23397 18383390 (Pubitemid 351563996)
48. YR Lee SH Kweon KB Kwonc, et al. 2009 Inhibition of IL-1beta-mediated inflammatory responses by the IkappaBalpha super-repressor in human fibroblast-like synoviocytes Biochem Biophys Res Commun 378 90 94 10.1016/j.bbrc.2008.11.002 19007749
49. E Lubberts 2008 IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis? Cytokine 41 84 91 10.1016/j.cyto.2007.09.014 18039580
50. E Lubberts L van den Bersselaar B Oppers-Walgreen, et al. 2003 IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappaB ligand/osteoprotegerin balance J Immunol 170 2655 2662 12594294
51. RN Maini M Feldmann 2002 How does infliximab work in rheumatoid arthritis? Arthritis Res 4 Suppl 2 S22 S28 10.1186/ar549 12110154
52. RN Maini PC Taylor 2000 Anti-cytokine therapy for rheumatoid arthritis Annu Rev Med 51 207 229 10.1146/annurev.med.51.1.207 10774461 (Pubitemid 30216034)
53. R Maini E St Clair F Breedveld, et al. 1999 Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group Lancet 354 1932 1939 10.1016/S0140-6736(99) 05246-0 10622295
54. RN Maini PC Taylor J Szechinski, et al. 2006 Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate Arthritis Rheum 54 2817 2829 10.1002/art.22033 16947782 (Pubitemid 44497760)
55. KM McKown LD Carbone SB Kaplan, et al. 1999 Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis Arthritis Rheum 42 1204 1208 10.1002/1529-0131(199906)42:6<1204::AID- ANR17>3.0.CO;2-U 10366113 (Pubitemid 29268957)
56. SY Min SY Hwang KS Park, et al. 2004 Induction of IL-10-producing CD4+CD25+T cells in animal model of collagen-induced arthritis by oral administration of type II collagen Arthritis Res Ther 6 R213 R219 10.1186/ar1169 15142267
57. P Miossec 2007 Interleukin-17 in fashion, at last: ten years after its description, its cellular source has been identified Arthritis Rheum 56 2111 2115 10.1002/art.22733 17599728 (Pubitemid 47173557)
58. KM Mohler DS Torrance CA Smith, et al. 1993 Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists J Immunol 151 1548 1561 8393046
59. LW Moreland EE Morgan TC Adamson 3rd, et al. 1998 T cell receptor peptide vaccination in rheumatoid arthritis: a placebo-controlled trial using a combination of Vbeta3, Vbeta14, and Vbeta17 peptides Arthritis Rheum 41 1919 1929 10.1002/1529-0131(199811)41:11<1919::AID-ART5>3.0.CO;2-1 9811045 (Pubitemid 28506680)
60. L Moreland M Schiff S Baumgartner, et al. 1999 Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial Ann Intern Med 130 478 486 10075615 (Pubitemid 29135800)
61. LW Moreland SB Cohen SW Baumqartner, et al. 2001 Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis J Rheumatol 28 1238 1244 11409115
62. LW Moreland R Alten F Van den Bosch, et al. 2002 Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion Arthritis Rheum 46 1470 1479 10.1002/art.10294 12115176 (Pubitemid 34620192)
63. N Nishimoto T Kishimoto 2006 Interleukin 6: from bench to bedside Nat Clin Pract Rheumatol 2 619 626 10.1038/ncprheum0338 17075601 (Pubitemid 44650950)
64. N Nishimoto K Yoshizaki N Miyasaka, et al. 2004 Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial Arthritis Rheum 50 1761 1769 10.1002/art.20303 15188351 (Pubitemid 38725087)
65. N Nishimoto Y Kanakura K Aozasa, et al. 2005 Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease Blood 106 2627 2632 10.1182/blood-2004-12-4602 15998837 (Pubitemid 41510733)
66. N Nishimoto J Hashimoto N Miyasaka, et al. 2007 Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X ray reader-blinded randomised controlled trial of tocilizumab Ann Rheum Dis 66 1162 1167 10.1136/ard.2006.068064 17485422 (Pubitemid 47309731)
67. N Nishimoto N Miyasaka K Yamamoto, et al. 2009 Long-term safety and efficacy of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in anti-interleukin-6 receptor monoclonal antibody, in (the STREAM study): evidence of safety and efficacy in a 5-year extension study Ann Rheum Dis 68 1580 1584 10.1136/ard.2008.092866 19019888
68. G Nuki B Bresnihan MB Bear, et al. 2002 Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial Arthritis Rheum 46 2838 2846 10.1002/art.10578 12428223 (Pubitemid 35315874)
69. D O' Gradaigh D Ireland S Bord, et al. 2004 Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor alpha, interleukin 1, and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclasts Ann Rheum Dis 63 354 359 10.1136/ard.2003.008458 15020327 (Pubitemid 38453299)
70. H Park Z Li XO Yang, et al. 2005 A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17 Nat Immunol 6 1133 1141 10.1038/ni1261 16200068 (Pubitemid 41541791)
71. K Pfeffer 2003 Biological functions of tumor necrosis factor cytokines and their receptors Cytokine Growth Factor Rev 14 185 191 10.1016/S1359-6101(03) 00022-4 12787558 (Pubitemid 36693140)
72. PJ Richards MA Nowell S Horiuchi, et al. 2006 Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis Arthritis Rheum 54 1662 1672 10.1002/art.21818 16646038
73. EM Ruderman 2005 Current and future pharmaceutical therapy for rheumatoid arthritis Curr Pharm Des 11 671 684 10.2174/1381612053381954 15720281 (Pubitemid 40277874)
74. K Sato 2008 Th17 cells and rheumatoid arthritis-from the standpoint of osteoclast differentiation Allergol Int 57 109 114 10.2332/allergolint.R-07-158 18427163 (Pubitemid 351897664)
75. DL Scott GH Kingsley 2006 Tumor necrosis factor inhibitors for rheumatoid arthritis N Engl J Med 355 704 712 10.1056/NEJMct055183 16914706 (Pubitemid 44244541)
76. J Sieper S Kary H Sorensen, et al. 1996 Oral type II collagen treatment in early rheumatoid arthritis. A double-blind, placebo-controlled, randomized trial Arthritis Rheum 39 41 51 10.1002/art.1780390106 8546737 (Pubitemid 26036376)
77. JS Smolen A Beaulieu A Rubbert-Roth, et al. 2008 Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial Lancet 371 987 997 10.1016/S0140-6736(08)60453-5 18358926
78. V Strand R Kimberly JD Isaacs 2007 Biologic therapies in rheumatology: lessons learned, future directions Nat Rev Drug Discov 6 75 92 10.1038/nrd2196 17195034 (Pubitemid 46020288)
79. DE Trentham RA Dynesius-Trentham EJ Orav, et al. 1993 Effects of oral administration of type II collagen on rheumatoid arthritis Science 261 1727 1730 10.1126/science.8378772 8378772
80. NM Tsuji K Mizumachi J Kurisaki 2001 Interleukin-10 secreting Peyer's patch cells are responsible for active suppression in low-dose oral tolerance Immunology 103 458 464 10.1046/j.1365-2567.2001.01265.x 11529936 (Pubitemid 32744392)
81. AK Ulfgren U Andersson M Engstrom, et al. 2000 Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis Arthritis Rheum 43 2391 2396 10.1002/1529-0131(200011)43:11<2391::AID-ANR3>3.0.CO;2-F 11083259 (Pubitemid 30829260)
82. LB van de Putte C Atkins M Malaise, et al. 2004 Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed Ann Rheum Dis 63 508 516 10.1136/ard.2003.013052 15082480 (Pubitemid 38530193)
83. A Van der Aa N Hellings R Medaer, et al. 2003 T cell vaccination in multiple sclerosis patients with autologous CSF-derived activated T cells: results from a pilot study Clin Exp Immunol 131 155 168 10.1046/j.1365-2249. 2003.02019.x 12519400 (Pubitemid 36098836)
84. JM Van Laar AM Miltenburg MJ Verdonk, et al. 1993 Effects of inoculation with attenuated autologous T cells in patients with rheumatoid arthritis J Autoimmun 6 159 167 10.1006/jaut.1993.1013 8098938 (Pubitemid 23161774)
85. MP Vincenti CI Coon CE Brinckerhoff 1998 Nuclear factor kappaB/p50 activates an element in the distal matrix metalloproteinase 1 promoter in interleukin-1beta-stimulated synovial fibroblasts Arthritis Rheum 41 1987 1994 10.1002/1529-0131(199811)41:11<1987::AID-ART14>3.0.CO;2-8 9811054 (Pubitemid 28506689)
86. HL Weiner 1997 Oral tolerance: immune mechanisms and treatment of autoimmune diseases Immunol Today 18 335 343 10.1016/S0167-5699(97)01053-0 9238837 (Pubitemid 27314470)
87. HL Weiner A Friedman A Miller, et al. 1994 Oral tolerance: immunologic mechanisms and treatment of animals and human organ-specific autoimmune disease by oral administration of autoantigens Annu Rev Immunol 12 809 837 10.1146/annurev.iy.12.040194.004113 8011298
88. H Yamada Y Nakashima K Okazaki, et al. 2008 Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis Ann Rheum Dis 67 1299 1304 10.1136/ard.2007.080341 18063670
89. E Yelin C Henke W Epstein 1987 The work dynamics of the person with rheumatoid arthritis Arthritis Rheum 30 507 512 10.1002/art.1780300504 3593434 (Pubitemid 17108103)
90. E Yelin D Lubeck H Holman, et al. 1987 The impact of rheumatoid arthritis and osteoarthritis: the activities of patient with rheumatoid arthritis and osteoarthritis compared to control J Rheumatol 14 710 717 3668977
91. S Yokota T Imagawa M Mori, et al. 2008 Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial Lancet 371 998 1006 10.1016/S0140-6736(08)60454-7 18358927
92. R Zeltser L Valle C Tanck, et al. 2001 Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein Arch Dermatol 137 893 899 11453808
93. E Zintzaras IJ Dahabreh S Giannouli, et al. 2008 Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens Clin Ther 30 1939 1955 10.1016/j.clinthera. 2008.11.007 19108784
94. M Ziolkowska A Koc G Luszczykiewicz, et al. 2000 High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism J Immunol 164 2832 2838 10679127